The next‑generation, AI‑designed pan‑EGFR inhibitor for EGFR‑mutant lung cancer significantly expands the Company's oncology pipeline Targeting a $16.2 Billion Market Opportunity Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it has entered into binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment. John Yu, M.D., Kairos Pharma Chief Executive Officer, commented: "The signing of binding terms to acquire CL‑273 represents a pivotal step in building Kairos Pharma's next generation of targeted therapies for EGFR‑mutant lung cancer. Th

3/2/26 6:30:00 AM ET

$KAPA

Biotechnology: Pharmaceutical Preparations

Health Care

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics

Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market. Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-sma

2/26/26 7:00:00 AM ET

$KAPA

Biotechnology: Pharmaceutical Preparations

Health Care

Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference

CSO Neil Bhowmick to deliver company presentation and will be available for investor meetings Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it will participate in the DealFlow Discovery Conference, taking place Jan. 28-29, 2026, at the Borgata Hotel in Atlantic City, NJ. Kairos Pharma Chief Scientific Officer Neil Bhowmick will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Event Details: 3rd Annual DealFlow Discovery Conference The Borgata Hotel, Casino & Spa Atlantic City, NJ Jan. 28-29, 2026 Investors interested in schedul

1/20/26 8:00:00 AM ET

$KAPA

Biotechnology: Pharmaceutical Preparations

Health Care

SEC Form EFFECT filed by Kairos Pharma Ltd.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$KAPA

SEC Form EFFECT filed by Kairos Pharma Ltd.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$KAPA

$KAPA
Insider Trading

Chief Scientific Officer Bhowmick Neil was granted 171,756 shares, increasing direct ownership by 15% to 1,311,739 units (SEC Form 4)

Director Bae Hyun W. was granted 29,084 shares, increasing direct ownership by 66% to 73,370 units (SEC Form 4)

VP of Research and Development Murali Ramachandran was granted 152,672 shares, increasing direct ownership by 104% to 299,529 units (SEC Form 4)

$KAPA
Insider Purchases

VP of Research and Development Murali Ramachandran bought $318 worth of shares (200 units at $1.59), increasing direct ownership by 0.15% to 133,057 units (SEC Form 4)

Chief Financial Officer Samuelson Doug bought $3,750 worth of shares (2,500 units at $1.50), increasing direct ownership by 4% to 60,796 units (SEC Form 4)

CEO and Chairman Yu John S bought $5,760 worth of shares (4,000 units at $1.44), increasing direct ownership by 0.07% to 5,341,837 units (SEC Form 4)

$KAPA
SEC Filings

Kairos Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

Kairos Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits